Key result
Intravenous statins during ischemia limit post-MI injury in preclinical models.
Why the study?
Does intravenous statin administration during ischemia exert cardioprotective effects in myocardial infarction?
Does intravenous statin administration during ischemia exert cardioprotective effects in myocardial infarction?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The main contribution of this study is demonstrating for the first time that intravenous administration of atorvastatin during the ischemic event itself has a significantly greater impact on reducing cardiac damage than administration of a pre-infarction oral loading dose.”
“Working with a model that closely reproduces what occurs in patients and combining it with advanced cardiac imaging techniques allowed us to evaluate how the timing and route of treatment administration influence cardiac damage. This design gave us the opportunity to analyze not only the initial injury but also the subsequent evolution of the heart after myocardial infarction.”
Intravenous statin administration during ischemia may offer a therapeutic strategy to limit post-MI cardiac injury.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mendieta et al. (2019) studied this question. Intravenous statin administration during ischemia exerts cardioprotective effects against post-myocardial infarction injury.
Synapse has enriched 10 related papers. Consider them for comparative context: